Case-based discussion on which mCSPC patients benefit from early treatment intensification

COR2ED Medical Education

COR2ED Medical Education: Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast.

The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and discuss the patient subgroups that benefit the most from early treatment intensification.

A number of patient scenarios are considered alongside the efficacy of the novel hormonal combinations, adverse event profiles, drug to drug interactions, volume of disease, age, comorbidities and patient risk.